Pneumococcal meningitis in a patient with severe COVID-19 on dexamethasone and tocilizumab: A case report

Abstract

Although various therapeutic agents have been tried for coronavirus disease-2019 (COVID-19) and evidence has accumulated, the risk of secondary infection is increased by underlying disease and immunosuppressive drugs. We report a case of pneumococcal meningitis in a patient with severe COVID-19 who was receiving dexamethasone and tocilizumab. The patient's symptoms improved with appropriate diagnosis and antimicrobial therapy, and she fortunately returned to society without any neurological sequelae of meningitis.

Keywords

• COVID-19
• SARS-CoV-2
• Tocilizumab
• Streptococcus pneumoniae
• Meningitis
• Secondary-infection